Biosimilar Meeting Requests Increase, But FDA Cancels Some For Lack Of Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Some early meeting requests from potential biosimilar sponsors were not held because they did not include the necessary information for FDA to give development advice.